Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Guillaume Beziat; Martin Gauthier; Caroline Protin; Lucie Oberic; Fleur Lerebours; Jasmine Carlier; Loïc Ysebaert

doi:10.1002/ccr3.2580

Clinical Case Reports (Feb 2020)

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Guillaume Beziat,
Martin Gauthier,
Caroline Protin,
Lucie Oberic,
Fleur Lerebours,
Jasmine Carlier,
Loïc Ysebaert

Affiliations

Guillaume Beziat: Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France
Martin Gauthier: Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France
Caroline Protin: Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France
Lucie Oberic: Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France
Fleur Lerebours: Department of Neurology CHU Purpan Toulouse France
Jasmine Carlier: Department of Neurology CHU Purpan Toulouse France
Loïc Ysebaert: Department of Hematology Institut Universitaire du Cancer de Toulouse‐Oncopole Toulouse France

DOI: https://doi.org/10.1002/ccr3.2580
Journal volume & issue: Vol. 8, no. 2
pp. 269 – 273

Abstract

Read online

Abstract Venetoclax with high‐dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords